Danaher Ventures

Danaher Ventures is the venture capital entity of Danaher Corporation, the Washington, D.C. based diversified science and technology conglomerate. The arm funds breakthrough life sciences research tools and highly specialized clinical diagnostics, aligning with Danaher’s operating company portfolio that includes Beckman Coulter, Cepheid, Leica Biosystems, and others. Founders building tools across genomics, proteomics, single-cell analysis, molecular diagnostics, pathology, and bioprocessing platforms are within scope. The fund leverages the parent’s deep operating expertise via the Danaher Business System, which can be a meaningful asset for portfolio companies needing operational maturation.

Danaher Ventures invests at Series A and Series B with check sizes from $5M to $25M. It is United States based and focuses on life sciences tools and diagnostics. There is no stated AI focus, though computational platforms in genomics and pathology increasingly intersect with the thesis.

Founders should expect strategic diligence that weighs distribution synergy with Danaher operating companies and operational rigor. Clarity on commercial milestones, regulatory pathway for diagnostics, and the potential acquisition pathway by a Danaher operating company is helpful. Limited public information exists about specific deal contacts and portfolio composition, so introductions via Danaher operating company executives or scientific advisors are the most credible route.